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Cytokine regulation of adenylate cyclase activity in LLC-PK1 cells.
Although several cytokines have been demonstrated to exert pleiotro-
pic responses, there is little information on cytokine regulation of renal
tubular epithelial cell function. In the present studies, we find that both
T cell-derived (tumor necrosis factor-/3 and interleukins 2 and 3) and
monocyte/macrophage derived (tumor necrosis factor alpha and inter-
leukin 1/3) cytokines promote basal, arginine vasopressin- and forsko-
lin-stimulated adenylate cyclase activity in cultured LLC-PK1 cells. No
effect of TNF, IL-1/3, and IL-2 to stimulate protein kinase C activity
was observed. TNF-/3, IL-13 and IL-2 also modestly stimulated 3H
release from 3H-arachidonic acid labeled cells. Mepacrine, a phospho-
lipase A inhibitor, prevented TNF-/3 stimulation of 3H release from
3H-arachidonic acid labeled cells and TNF-/3 potentiation of adenylate
cyclase activity. TNF-/3 potentiation of adenylate cyclase activity and
stimulation of 3H release from 3H arachidonic acid labeled cells was not
prevented by pertussis toxin. These results demonstrate that several
cytokines can stimulate adenylate cyclase activity while not affecting
protein kinase C activity in cultured renal tubular epithelial cells. The
effect of TNF-/3 to stimulate adenylate cyclase appears to occur
independent of pertussis toxin-sensitive substrate and may involve
activation of phospholipase A.
The term cytokine refers to a large group of soluble mole-
cules, generally glycoproteins, that are produced by activated T
lymphocytes, monocytes, macrophages, fibroblasts and stromal
cells [1]. Initially, cytokines were thought to mediate immune
and inflammatory responses [1]. More recently it has become
recognized that cytokines are pleiotropic with multiple biologic
activities [1].
With regard to the kidney, several cytokines have been found
to exert a variety of actions in glomerular mesangial cells [2—9].
There is, however, limited information on the effect of cyto-
kines on renal tubular epithelial cells [10—12]. Moreover, the
signal transduction pathways by which cytokines induce their
biological effects remain unclear [1—13]. The present studies
were therefore undertaken to examine the effect of both T
cell-derived (tumor necrosis factor-beta and interleukins 2 and
3) and macrophage/monocyte-derived (tumor necrosis factor-
alpha and interleukin 1) cytokines on signal transduction in
cultured renal tubular epithelial cells. Our results demonstrate
that multiple cytokines promote adenylate cyclase activity
while not affecting protein kinase C activity in LLC-PK1 cells.
Methods
Materials
Arginine vasopressin (AVP), indomethacin, mepacrine, 4-/3-
phorbol 12-myristate 13-acetate (PMA), prostaglandin E2
(PGE2) and prostacyclin were obtained from Sigma. Phospha-
tidylserine and diolein were obtained from Avanti Polar Lipids.
Forskolin was obtained from Calbiochem and pertussis toxin
from List. Cayman was the source of 1 1-deoxy prostaglandin
E1. Human recombinant TNF-a, TNF-f3, interleukin 1 beta
(IL-1/3) were obtained from R and D Systems. Human recom-
binant interleukin 2 (IL-2) and interleukin 3 (IL-3) were pro-
vided by Dr. Steven Gillis of Immunex Research and Develop-
ment Corporation. [a-32P]ATP (30 to 40 Citmmol), [gamma-32P]
ATP (25 to 35 Cilmmol) and 3H-arachidonic acid (70 to 80
Ci/mmol) were obtained from DuPont-New England Nuclear
(Boston, Massachusetts, USA). Amersham was the source of
the PGE2 radioimmunoassay kit.
Cell and culture conditions
LLC-PK1 cells were obtained from the American Type
Culture Collection. Membranes for adenylate cyclase assays
were obtained from cells grown on 75-cm2 plastic flasks. Cells
were grown in RPMI 1640 medium (Irvine Scientific) which was
supplemented with 200 mg% sodium bicarbonate, 16 ms
Hepes, 100 U/ml penicillin, and 200 p.g/ml streptomycin. New-
born calf serum (6%) was added to the media for the initial three
to seven days of growth while monolayer proliferation was
established after which all cultures received serum-free media.
Serum-free conditions were used for 48 hours prior to each
experiment. The cultures were maintained at 37°C in a humid-
ified atmosphere of 95% air and 5% CO2. Cell growth was
monitored under an inverted microscope with phase optics
(Nikon 1M35) and typically reached confluence in five to seven
days. Confluent cultures were selected for biochemical studies.
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Crude membrane preparation
Confluent cultures were washed three times with 8 ml of cold
phosphate-buffered saline containing 0.9 mrs's CaCl2 and 0.5 mM
MgCI2 and the cells harvested by scraping three times with 4 ml
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of ice-cold EDTA (1 mM)/Tris (50 mM) buffer (pH 7.4). Mem-
branes were homogenized with 15 strokes of a Dounce homog-
enizer, centrifuged at 14,000 rpm at 4°C for five minutes, and
resuspended in 500 p1 of EDTA/Tris buffer.
Adenylate cyclase assay
Adenylate cyclase activity was measured using slight modi-
fications of previously described techniques and carried out in a
final volume of 50 1.d [14—16]. Ten pl of membrane preparation
(approximately 10 g of protein) was added to an assay mixture
containing 0.25 mti Na2EDTA, 5.25 mtvt MgCI2, 1.0mM cAMP,
1.0 m purified [a-32P]ATP (2 X 106 cpm) in 25 mri Tris-HC1
(pH 7.4) and an ATP-regenerating system consisting of 20 mM
creatinine phosphate and 100 lU/mi creatinine phosphokinase.
After a 10 minute incubation at 30°C, the reaction was stopped
by adding 150 jil of ice-cold stopping solution containing 3.3 mrvi
ATP, 4 m cAMP, 40 mit Tris-HCI, and 10,000 to 15,000 cpm
of [3H]cAMP for recovery, which averaged 50 to 70%.
[32P]cAMP was separated from unreacted [a-32P]ATP by a
sequential two-step elution over Dowex and alumina columns.
Assays were carried out in triplicate with a standard error of the
mean usually less than 2 to 3%. Either preliminary experiments
were done to document that the vehicles used for the tested
cytokines did not affect adenylate cyclase activity or the
vehicles were used in control experiments.
Protein kinase C assay
Cells were grown to confluence as described above and
protein kinase C activity in the cytosol and particulate fractions
measured as previously described [15, 161. After exposure to
test agents, the cultures were washed with ice-cold PBS,
scraped into 1 ml of homogenizing buffer (20 mtvt Tris, 2 mM
EGTA, 50 m 2-mercaptoethanol, pH 7.5) and sonicated for 2
x 15 seconds at the minimum output of a Branson sonicator.
The sonicate was centrifuged at 1,000 g for 10 minutes to pellet
cell debris and nuclei, and the supernatant was subjected to
ultracentrifugation for 60 minutes at 100,000 g to obtain the
cytosolic fraction. The particulate fraction was resuspended in
1 ml of the same buffer containing 0.1% Triton X-100, sonicated
as above, and again subjected to centrifugation for 60 minutes at
100,000 g. The supernatant thus obtained was used to assay for
protein kinase C contained in a particulate fraction. Protein
kinase C was assayed in a reaction mixture containing 5 mol
Tris/HCI, pH 7.5, 50 ig histone, 60 sM phosphatidylserine, 8
sM diolein, 1.25 jsmol MgCl2, varying concentrations of CaC12,
and 2.5 nmol ATP containing approximately 106 cpm of
[gamma32P]ATP in a final volume of 0.25 ml. The trichioroace-
tic acid-precipitable material was collected by filtration through
a 0.45 m nitrocellulose membrane filter (Millipore) washed
extensively and analyzed by liquid scintillation counting. Pro-
tein kinase activity was calculated as the stimulated activity
determined in the presence of calcium and various activators
minus the basal activity determined without calcium or other
activators.
Arachidonic acid and/or metabolite release assays
These studies were performed by slight modifications of
described techniques [17, 18]. Cells were grown in 35 mm
dishes and labeled for 18 hours with 0.33 sCi/ml [3H]-arachi-
donic acid in RPM! 1640 medium (Irvine Scientific) which was
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Fig. 1. Effect of TNF-13 (10_Jo M) on AVP- (A) and forskolin- (B)
stimulated adenylate cyclase activity. Symbols are: (O----O) TNF-/3;(• •) control. LLC-PK1 cells were exposed to TNF-/3 for 5 min-
utes, cell membranes prepared and adenylate cyclase activity deter-
mined as described in Procedures. Each data point represents the mean
SEM of 4 separate experiments done in triplicate. TNF-f3 significantly
increased adenylate cyclase activity at each concentration of agonist.
supplemented with 200 mg% sodium bicarbonate, 16 mrt Hepes
and 0.5% fetal calf serum. At the end of the labeling period,
cells were washed four times with RPM! and 0.5% fetal calf
serum. One ml of RPM! containing 0.5% fetal calf serum with or
without the test agent was added and the cells were incubated at
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Fig. 2. Effect of control ( •) 1O0 M IL-
1/3 (O----O), IL-2 (L1—D) and IL-3 (Lr—A)
on AVP- (A) and forskolin- (B) stimulated
adenylate cyclase activity in LLC-PK1 cells.
Intact LLC-PK1 cells were exposed to the
indicated cytokine for 5 minutes, cell
membrane prepared and adenylate cyclase
measured as described in Procedures. Each
data point represents the mean SCM of 3
separate experiments done in triplicate. Each
of the tested cytokines significantly (P < 0.05)
increased adenylate cyclase activity when
compared with control values at each
concentration of agonist, except for IL-3
which did not significantly increase iO M
forskolin-stimulated adenylate cyclase
activity.
37°C for the indicated period. The medium was aspirated and
counted in a liquid scintillation counter. Three wells were
studied under each condition of the assay and the values were
averaged to obtain an N of 1 for that condition. The values are
expressed as either actual dpm (experimental-control) or per-
cent dpm increase relative to simultaneously studied controls.
Prostaglandin E2 assay
Cells were grown to confluence in 24 well dishes using RPM!
media with 6% fetal calf serum. For 12 to 24 hours prior to
assay, the cells were exposed to 2% fetal calf serum. Cells were
washed three times with Krebs-Ringer solution containing 1 mM
calcium. Control cells and experimental cells were incubated
for 30 to 60 minutes after which the fluid was removed from
each well into polypropylene tubes and frozen at —70°C. PGE2
was measured within one to three days using an Amersham kit
(#RPA539).
Protein assay
Protein was estimated by a modified Lowry method using
bovine serum albumin as a standard.
Statistical analyses
All calculations and analyses were carried out using at AT1'
PC-6300 desktop computer and ABSTAT software. All data
were expressed at the mean SE. Statistical analyses were
performed using paired and unpaired Student's t-test and
ANOVA where appropriate. A P value of <0.05 was consid-
ered significant.
Results
In preliminary dose-response experiments, we found that
TNF-/3 reproducibly potentiated basal and agonist-stimulated
adenylate cyclase activity at threshold concentrations ranging
from 1012 to 10_11 M. Maximal stimulation occurred at 10_Jo
M. In preliminary time course experiments, we found that
exposure of intact LLC-PK1 cells to 10 o M TNF-13 for one,
five and 15 minutes produced a comparable increase in cell
membrane adenylate cyclase activity. The effect of five minutes
exposure to l0'° M TNF-f3 on basal, AVP- and forskolin-
stimulated adenylate cyclase activity is in Figure 1. TNF-/3
significantly (P < 0.05) increased basal, AVP- and forskolin (all
concentrations tested)-stimulated adenylate cyclase activity.
Comparable stimulation of basal, AVP- and forskolin-stimu-
lated adenylate cyclase activity was also seen with 1O'° M
TNFs (data not shown). TNF-/3 also significantly increased
AVP-stimulated adenylate cyclase activity when added directly
to LLC-PK1 crude membranes. In these paired studies, adenyl-
ate cyclase activity (pmol cAMP/mg/mm) stimulated by
l0_8 and iO M AVP was significantly higher (P < 0.05) in the
presence than in the absence of TNF-/3 (10 M) and was 39.7
2.0 versus 33.8 2.1, 74.8 3.9 versus 65.1 4.2 and 83.8
4.9 versus 70.2 4.0, respectively.
To determine if the effect of TNF to stimulate adenylate
cyclase activity was specific for this cytokine, additional studies
were performed. Human recombinant IL-l/3, IL-2 and IL-3 also
significantly (P < 0.05) potentiated basal, AVP- and forskolin-
stimulated adenylate cyclase activity (Fig. 2).
Since activation of protein kinase C promotes adenylate
cyclase activity in LLC-PK1 cells [16], the effect of five minutes
exposure to TNF-/3 on LLC-PK1 cell protein kinase C activity
was measured (Fig. 3). The phorbol ester PMA (l0— M)
significantly increased protein kinase C specific activity and
translocated this activity from a soluble to a particulate cell
fraction. By contrast, TNF-/3 (Fig. 3) did not affect either total
activity or cellular localization of protein kinase C. In additional
studies, none of the other cytokines tested including TNFa
(control 0.660 0.16, 10_Jo M TNFa 0.579 0.09 and l0 M
TNFa 0.631 0.12, nmol 32P/mglmin, N = 5), IL-l-/3 (control
0.801 0.11, 10_Jo M IL-l/3 0.718 0.06 and l0 M IL-l/3
0.759 0.10 nmol 32P/mg/min, N 5) and IL-2 (control 0.540
0.10, l0 M IL-2 0.434 0.08 and l0 M IL-2 0.408 0.08
nmol 32P/mg/min, N = 5) significantly affected specific activity
or localization of protein kinase C activity. Together these
results suggest that the effect of TNF, IL-lp and IL-2 to
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Fig. 4. Effect of TNF-/3 on 3H release from 3H-arachidonic acid
labeled LLC-PK1 cells. Intact LLC-PK1 cells were exposed to the noted
concentrations of TNF in the absence or presence of mepacrine for S
minutes. The individual data points represent the mean SEM of
experimental control DPM found in the media. At 10° M, TNF-/3
significantly increases DPM and this effect was abolished in the
presence of mepacrine pretreatment (30 mm).
stimulate adenylate cyclase activity occurs independent of
protein kinase C activity.
TNF activates phospholipase A in several cell types [2, 4, 6,
10, 13, 19—211. To indirectly assess if TNF-/3 activates phos-
pholipase A in LLC-PK1 cells, intact cells were incubated for 18
hours with 3H-arachidonic acid then exposed for five minutes to
several cytokines. The effect of TNF-$ on 3H release is in
Figure 4. TNF-/3 resulted in a modest, significant release of 3H
from 3H-arachidonic acid labeled cells. This release of 3H was
65 9% greater than observed in control cells not exposed to
TNF-p studied over the same time interval. This release of 3H
could be completely prevented by pre-treatment with i0 M
mepacrine, a phospholipase A inhibitor. We also examined the
effect of IL-1J3 and IL-2 on 3H release from 3H arachidonic acid
0 11 10 9 10
+
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Fig. 3. Effect of TNF-p and PMA on protein
kinase C activity in LLC-PK1 cells. Intact
cells were exposed for 5 minutes to the noted
concentrations of TNF-/3 or to l0 M PMA.
Cell fractions were obtained and analyzed for
protein kinase C as described in Procedures.
Each bar represents the mean SEM of 5
experiments. The number denoted in
parentheses at the bottom of each column
— / represents the percentage of protein kinase C
found in a particulate fraction. * P < 0.05
when compared with control.
labeled cells. At l0'° M, IL-113 stimulated release of 3H from
labeled cells at a rate of 13 4% greater than control cells (N
4) while i0 M IL-2 stimulated 3H release at a rate of 49
10% greater than control cells (N = 5). Pretreatment with lO
M mepacrine completely prevented any increase in 3H release
from 3H-arachidonic acid labeled cells with either 10— 10 M
IL-1f3 or IL-2 relative to control cells. These observations
suggest that TNF-J3, IL-1f3 and IL-2 stimulate release of ara-
chidonic acid and/or its metabolites in LLC-PK1 cells and this
release is blocked by mepacrine.
To determine the role of phospholipase A activation in TNF
potentiation of adenylate cyclase activity, the paired experi-
ments depicted in Figure 5 were done. At 10_b M, TNF-/3
stimulation of adenylate cyclase occurred in the absence but not
in the presence of phospholipase A inhibition with mepacrine,
suggesting the possibility that either arachidonic acid or one of
its metabolic products was responsible for TNF-/3 potentiation
of adenylate cyclase activity.
Arachidonic acid can be metabolized via cyclooxygenase to
prostaglandins, prostacyclin and thromboxanes, via lipooxyge-
nase to hydroperoxyeicosatetraenoic acid and leukotrienes and
via cytochrome P450 monooxygenase to epoxyeicostraenoic
acids. The two major cyclooxygenase products produced by
most renal tubular epithelial cells are prostaglandin E2 and
prostacyclin. Since prostaglandins and prostacyclin can regu-
late adenylate cyclase activity in several cell types [22, 23], we
determined if PGE2 and prostacyclin are candidate effectors for
TNF-/3 potentiation of adenylate cyclase activity in LLC-PK1
cells, At l0 M, PGE2 did not affect AVP-stimulated adenyl-
ate cyclase activity. At tO_b, iO and 108 M, PGE2 potenti-
ated AVP-stimulated adenylate cyclase activity by 8 3, 12
2 and 27 4%, respectively. The effect of io_ M PGE2 on
AVP-stimulated adenylate cyclase activity is depicted in Figure
6. To clarify the prostaglandin receptor subtype involved in
PGE2 potentiation of adenylate cyclase activity [24], the effect
of 1 1-deoxy prostaglandin E1 was measured (Table I). The
effect of both prostaglandin E2 (Fig. 6) and 1 1-deoxy prosta-
glandin E1 (Table 1) to potentiate AVP-stimulated adenylate
cyclase activity suggest participation of the EP2 subtype of
Fig. 5. Effect of mepacrine pretreatment on
TNF-13 potentiation of A VP-stimulated
adenylate cyclase activity in LLC-PK1 cells.
Symbols are (0) TNF-13; (•) control. Intact
LLC-PK1 were pre-treated (30 mm) with i0
M mepacrine (B) or mepacrine carrier solution
(control, A). Intact cells were then exposed to
the noted concentrations of AVP in the
presence and absence of 10- 10 M TNF-/3 for 5
minutes. Cell membranes were obtained and
analyzed for adenylate cyclase activity as
noted in Procedures. Each data point
represents the mean SEM of 4 paired
experiments performed in triplicate. TNF-p
significantly (P < 0.05) increased adenylate
cyclase activity at all AVP concentrations in
the absence, but not in the presence of
mepacrine.
prostaglandin receptor in this process [241. As noted in Table 1,
l0_8 M prostacyclin also modestly potentiates AVP-stimulated
adenylate cyclase activity as noted in other studies in renal
epithelial cells [22, 23].
Since our results suggest that cyclooxygenase products of
arachidonic acid are possible effectors for TNF potentiation of
adenylate cyclase activity, additional experiments were per-
formed. First, we attempted to determine if TNF stimulates
release of PGE2 from LLC-PK1 cells. In these paired studies (N
= 9) media from control and TNF-J3-treated cells (10 10 M for
30 mm) was assayed for PGE2 using radioimmunoassay. We
found very low levels of PGE2 in control cells (3.66 0.17
pg//.Lg proteinl3O mm) that did not significantly increase with
TNF treatment (3.70 0.32 pg/gIprotein/30 mm). Since it is
possible that our radioimmunoassay, under the conditions of
the experiment, was insufficiently sensitive to detect TNF-13-
stimulated PGE2 production, pharmacologic experiments were
performed. In these studies, we examined the effect of indo-
methacin pre-treatment (l0— M) on basal and AVP-stimulated
adenylate cyclase activity in the presence and absence of l0 10
M TNF-/3 (Table 2). Indomethacin prevented TNF-f3 potentia-
tion of AVP-stimulated but not basal adenylate cyclase activity.
To determine if lipooxygenase metabolites could play a role in
mediating TNF-f3 potentiation of AVP-stimulated adenylate
cyclase activity, preliminary studies were undertaken with
nordihydroguaiaretic acid (NGDA, 10 M). NGDA prevented
10 M TNF-13 to potentiate l0 AVP-stimulated adenylate
cyclase activity (41.3 4.1 to 41.1 3.6 in the presence and
44.7 3.5 to 62.1 8.4 pmol cAMP/mg/mm in the absence of
NGDA).
G proteins are known to regulate adenylate cyclase activity,
and several reports suggest a role for G proteins, including a
pertussis toxin-sensitive G protein, in receptor-stimulated acti-
vation of phospholipase A [25—27]. To determine if TNF-J3
activation of phospholipase A and potentiation of adenylate
cyclase activity involves a pertussis toxin-sensitive G protein,
two types of studies were done. First, we examined the effect of
10— 10 M TNF-p to stimulate 3H release from 3H-arachidonic
acid labeled in the absence and presence of pertussis toxin (1.0
g/ml for 18 hr). In five paired experiments, TNF increased 3H
release from 3H-arachidonic acid labeled cells by 34 4% in the
absence and 44 5% in the presence of pertussis toxin
pretreatment. In a second set of experiments, we examined the
effect of pertussis toxin pretreatment on TNF-/3 potentiation of
adenylate cyclase activity (Fig. 7). TNF-3 potentiated adenyl-
ate cyclase activity in both the presence and absence of
pertussis toxin.
Discussion
In the present studies we find that cytokines of diverse origin
including TNF, IL-1/3, IL-2 and IL-3 promote adenylate cyclase
activity in a cultured renal tubular epithelial cell line. This
stimulation occurs under basal conditions as well as in the
presence of a hormonal (AVP) and a direct (forskolin) activator
of adenylate cyclase. Our studies in crude membranes also
suggest that the effect of TNF-/3 to potentiate adenylate cyclase
activity occurs exclusively within the cell membrane compart-
ment. To our knowledge, an effect of any cytokine to stimulate
adenylate cyclase activity has not been previously reported.
Indirect observations support the contention that selected cy-
tokines are capable of stimulating adenylate cyclase activity in
several cell types. For example, TNFa is a potent stimulator of
cAMP accumulation in human fibroblasts and rat mesangial
cells [2, 28, 29]. Although these results are compatible with an
effect of TNFa to stimulate adenylate cyclase activity, TNFa
has also been reported to inhibit agonist stimulated cAMP
accumulation in other cell types [30—33]. With regard to other
cytokines, IL-i stimulates cAMP accumulation in most [28, 29,
34, 35] but not all studies [33]. Finally, in the only study directly
examining the effect of a cytokine on adenylate cyclase activity,
IL-2 has been reported to exert a protein kinase C-dependent
inhibition of adenylate cyclase activity in murine lymphocytes
[36]. Taken together, the results of the present and previous
studies suggest that several cytokines can stimulate adenylate
cyclase activity, thereby increasing cAMP and protein kinase A
in selected cell types. It is therefore possible that activation of
this signal transduction pathway may underlie some of the
physiologic response to cytokines [35].
Activation of protein kinase C can stimulate adenylate cy-
clase activity in LLC-PK1 cells [16]. In selected cells, some
cytokines have been reported to stimulate protein kinase C
activity [36, 37]. While it appears clear that serine and threonine
A Control
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Fig. 6. Effect of prostaglandin E2 on A VP-stimulated adenylate cy-
clase activity in LLC-PK1 cells. Symbols are: (O----O) PGE2; (• •)
control. Intact cells were exposed for 5 minutes to 10—8 M PGE2. Cell
membranes were obtained and adenylate cyclase assayed as described
in Procedures. Each data point represents the mean SEM of four
experiments performed in triplicate. PGE2 significantly (P < 0.05)
increased adenylate cyclase activity under each condition except in the
presence of iO M AVP.
phosphorylation occurs in response to tumor necrosis factor
and IL-i in some cells [3, 29], most studies have been unable to
detect an effect of cytokines to stimulate phosphoinositol turn-
over, increase intracellular calcium concentration or activate
protein kinase C [29, 39—41]. Our results are compatible with
these latter observations and suggest that the effect of TNF,
IL-i and IL-2 to stimulate adenylate cyclase activity occurs
independent of protein kinase C. It is noteworthy that recent
studies performed in renal glomerular mesangial cells suggest
that IL-i activates enzymes that increase phosphatidic acid
formation [5, 8]. In addition, phosphatidylinositol kinases that
potentially result in formation of phosphorylated derivatives of
phosphotidylinositoi have been described in response to IL-i
and IL-2 in fibroblasts and monocytes [41, 42]. Together, these
observations suggest that phosphatidic acid and novel phos-
phorylated derivatives of phosphatidylinositol may be impor-
tant second messengers of the actions of selected cytokines.
Recently, TNF and IL-i have been shown to increase binding
of GTP and GTP analogues to a variety of plasma membranes
and to stimulate GTPase activity [8, 43, 44]. In several studies,
Table 1. E
basal
ifect of prostacyclin and 1 1-deoxy prostaglandin E1 on
and AVP-stimulated adenylate cyclase activity
Condition
Adenylate cyclase activity pmol cAMP/mg/mm
Control Prostacyclin 11 Deoxy PGE1
Basal
AVP Ml0
10—8
1O
3.6 0.3 3.2 0.7 3.6 0.8
10.0 0.9 12.8 l.7 13.3 Ø•5a
40.9 1.6 46.3 2.3a 47.3 i.3a
45.6 1.9 53.3 2.8a 57.6 34a
AVPM
Adenylate cyclase activity pmol cAMP/mg/mm
Indomethacin (—) Indomethacin (+)
TNF(—) TNF(+) TNF(—) TNF(+)
0
10—8iO
6.7 1.1 9.1 1.6
48.7 3.3 59.4 4.Oa
51.9 3.5 62.9 37
8.2 1.5 11.1 l,oa
51.2 3.4 49.2 4.1
56.1 3.8 55.5 3.6
some of the biologic effects of TNF and IL-i can be attenuated
by pertussis toxin [8, 43, 44]. Together, these observations
suggest that a pertussis toxin sensitive G protein couples TNF
and IL-i receptors to a biologic response. Moreover, a pertus-
sis toxin sensitive G protein is well known to be involved in
regulation of phospholipase A2 and adenylate cyclase activity
[25—27]. We therefore examined the effect of pertussis toxin
pre-treatment on TNF-/3 potentiation of adenylate cyclase and
3H release from 3H-arachidonic acid labeled cells. Our results
suggest that the effect of TNF-/3 to promote adenylate cyclase
and stimulate 3H release from 3H-arachidonic acid labeled cells
occurs in the presence of high concentrations of pertussis toxin
suggesting an effect independent of a pertussis toxin sensitive G
protein.
In many cell types [13, 19—2 1] including rat mesangial cells [2,
4, 6], rabbit inner medullary cells, and cultures MDCK cells
[10—12], IL-i and TNF appear to activate phospholipase A2
with subsequent generation of products of both cyclooxygenase
(PGE2) and lipooxygenase [7, 10—12]. In the present studies, we
find TNF-/3, IL-1J3 and IL-2 stimulate 3H release from 3H-
arachidonic acid labeled cells and that this release can be
blocked by mepacrine, a putative phospholipase inhibitor.
Moreover, the effect of TNF to stimulate adenylate cyclase
activity does not occur in the presence of mepacrine and can be
attenuated by indomethacin. Finally, high concentrations of
exogenous PGE2 stimulate adenylate cyclase activity in our
cells. Together, these observations suggest that the effect of
selected cytokines that we observed to stimulate adenylate
2,,/
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LLC-PK1 cells were exposed to nothing (control), prostacyclin (10—8
M) or Il-deoxy prostaglandin E1 (10—8 M). Cells were harvested,
membranes obtained and adenylate cyclase assays performed as de-
scribed in the presence of the noted concentrations of AVP.
a P < 0.05 when compared with control
Table 2. Effect of TNF-f3 on arginine vasopressin-stimulated
adenylate cyclase activity in the presence and absence of
indomethacin
— —
'I
• II
0 9
AVP-/3, —log M
LLC-PK1 cells were pretreated for 20 minutes with l0 M indometh-
acm where indicated. Cells were then exposed to either TNF-f3 carrier
solution or to TNF-/3 (100 M) for 5 minutes. Cells were harvested,
membranes obtained and adenylate cyclase assays performed as de-
8 7 scribed in the presence of the noted concentrations of AVP.
a P < 0.05 when compared with control
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Fig. 7. Effect of pertussis toxin pre-treatment on TNF-13 potentiation
of adenylare cyclase activity in LLC-PKJ cells. Symbols are: (O----O)
TNF-f3; (S 5) control. Intact LLC-PKI cells were pre-treated (18
hr) with either pertussis toxin (1.0 g/ml, B) or pertussis toxin carrier
(control, A). Intact cells were then exposed to the noted concentrations
of AVP in the presence and absence of 10 M TNF-13 for 5 minutes.
Cell membranes were obtained and analyzed for adenylate cyclase
activity as described under Procedures. Each data point represents the
mean SEM of 4 paired experiments performed in triplicate. TNF-13
significantly (P < 0.05) potentiated basal and AVP-stimulated adenylate
cyclase activity in the presence and absence of pertussis toxin
pretreatment.
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